Global Risks

WHO ‘especially worried’ over Central and South America; hydroxycholoroquine trial resumes - WHO briefing

Director General of the World Health Organization (WHO) Tedros Adhanom Ghebreyesus speaks during a news conference on the situation of the coronavirus (COVID-2019), in Geneva, Switzerland, February 28, 2020. REUTERS/Denis Balibouse - RC2R9F9133SB

Director General of the World Health Organization (WHO) Tedros Adhanom Ghebreyesus speaks during a news conference on the situation of the coronavirus (COVID-2019), in Geneva, Switzerland, February 28, 2020. Image: REUTERS/Denis Balibouse - RC2R9F9133SB

Linda Lacina
Digital Editor, World Economic Forum
Our Impact
What's the World Economic Forum doing to accelerate action on Global Risks?
The Big Picture
Explore and monitor how COVID-19 is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:


  • World Health Organization held a media briefing on 3 June, to update the public on the COVID-19 coronavirus pandemic.
  • Clinical trial of hydroxycholoroquine resumed.
  • Intense spread continues in Central and South America.

The World Health Organization (WHO) said at a briefing Wednesday it would resume its trial of hydroxychloroquine, while expressing continued concern over the rise of COVID-19 coronavirus cases in the Americas.


What is the World Economic Forum doing about the coronavirus outbreak?

Hydroxychloroquine study can resume

The hydroxychloroquine section of the WHO's Solidarity Trial can resume after being paused temporarily on 25 May. The trial’s Data Safety and Monitoring Committee had halted the study as a precaution in response to safety concerns raised by an observational study published in the Lancet.

The Data Safety Monitoring Board’s review has been completed, and today WHO Director-General Dr Tedros Adhanom Ghebreyesus said that given the current mortality data available, there was no reason to discontinue the hydroxychloroquine arm of the international trial.


The WHO said the review highlights the importance of randomized trials, especially in emergency situations such as COVID-19, to understand which drugs or strategies could reduce illness. “Observational studies have limitations,” said Dr Soumya Swaminathan, WHO Chief Scientist. “You can do analysis, but there are so many potential biases in the way that patients are managed in a clinical setting that the only way to get definite answers is to be when conducted randomized trials.”

Vigilance key, pandemic “far from over”
While cases have begun to decline in certain parts of Europe, the virus is “far from over.” In fact, as the Director-General explained in a statement, more than 100,000 cases of COVID-19 have been reported to the WHO for each of the past five days.

One key danger, said Dr Maria Van Kerkhove, WHO Technical Lead, is complacency. “people grow tired,” she explained. “It's very difficult to keep up all of these measures. In some situations, these public health and social measures may need to be reintroduced again. And that may frustrate people. And that, in a sense, could make the virus more dangerous because people become complacent.”


Continued worries over the Americas

Thanks to rapid spread, the Americas continue to account for the the lion’s share of new cases, said the Director-General. “The number of cases reported each day in the Americas has been more than the rest of the world put together.”

While numbers are rising in regions such as the Eastern Mediterranean, South-East Asia and Africa, the WHO said it is “especially worried” about Central and South America.

Brazil currently has more than 553,000 cases, the second-highest in the world. Cases in countries such as Peru are also growing quickly.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Related topics:
Global RisksHealth and Healthcare Systems
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Global financial stability at risk due to cyber threats, IMF warns. Here's what to know

Spencer Feingold and Johnny Wood

May 15, 2024

About Us



Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum